This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see the "Risk Factors" section in Item 1A of Part I of this Form 10-K. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Form 10-K.
The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes to those statements contained elsewhere in this Annual Report on Form 10-K.
Overview We provide leading edge frozen logistics solutions to the life sciences industry. Since 2011, through the completion of the combination of our purpose-built and patented packaging, purpose-built cold chain logistics software platform information technologies and developed logistics knowhow known as "total turnkey management" we have provided logistics solutions for frozen shipping to the life sciences industry. Our solutions are disruptive to "older technologies" as they are more comprehensive and provide reliable, economic alternatives to existing products and services utilized for frozen shipping in the life sciences industry including stem cells, cell lines, vaccines, diagnostic materials, semen and embryos for in-vitro fertilization, cord blood, bio-pharmaceuticals, infectious substances and other items that require continuous exposure to frozen or cryogenic temperatures. In addition, our solutions can contribute significantly to the effectiveness, reliability and efficiency of clinical trials. Cryoport Express® Solutions include a cloud-based logistics management software platform branded as the CryoportalTM. The CryoportalTM software platform supports the management of the entire logistics process through a single interface which includes initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery.
Cryoport'stotal turnkey logistics solutions offer convenience, reliability and cost effectiveness, while the use of recyclable and reusable components provides "green," environmentally friendly solutions. The CryoportalTM provides an array of unique information dashboards and validation documentation for every shipment. 27 Integral to our logistics solutions are our Cryoport Liquid Nitrogen Dry Vapor Shippers (Cryoport Express® Shippers), which provide packaging that is cost-effective and reusable cryogenic transport containers (patented vacuum flasks) utilizing innovative liquid nitrogen (LN2) "dry vapor" technology. Cryoport Express® Shippers are non-hazardous, IATA ( International Air Transport Association) certified, and validated to maintain stable temperatures of minus 150° Celsius for a 10-plus day dynamic shipment period. The Company currently features two Cryoport Express®Shipper models, the Standard Dry Shipper (holding up to approximately 75-2.0 ml vials) and the High Volume Dry Shipper (holding up to approximately 500-2.0 ml vials). The Cryoport Express® Solutions includes document preparation, intervention capability, and recording and retaining a fully documented "chain-of-custody" and, at the client's option, "chain-of-condition" for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities shipped. This recorded and archived information allows our customers to meet the exacting requirements necessary for scientific work and for regulatory purposes. When a customized solution is not required, Cryoport Express®Solutions can be used by customers as a "turnkey" solution through direct access to the cloud-based CryoportalTMor by contacting Cryoport Client Care for order entry tasks. Cryoportprovides 24/7/365 logistics services through its Client Care team and also provides complete training and process management services to support each client's specific requirements. Amongst our solutions, we offer a "turnkey" solution, which can be accessed through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once the order is placed, we ship a fully charged Cryoport Express® Shipper to the customer who conveniently loads their frozen commodity into inner chamber of the shipper. The customer then closes the shipper and reseals the shipping box displaying the recipient's address ("Flap A") for pre-arranged carrier pick up. Cryoportarranges for the pick-up of the parcel by a shipping service provider for delivery to the customer's intended recipient. The recipient simply opens the box and shipper and removes the frozen commodity. The recipient only needs to reseal the box, displaying the nearest Cryoport Operations Centeraddress ("Flap B") and set out for pre-arranged carrier pick up. The Cryoport Express® Shipper is returned to us for cleaning, quality assurance testing, recharging and reuse of the Cryoport Express® Shipper. In late 2012, we shifted our focus from being a developer of cryogenic shippers and software to being a comprehensive frozen logistics solutions provider to the life sciences industry, which was accomplished by broadening our service offerings. Now, in addition to our "Turn-key Solution," we also provide the following value-added solutions that were developed to address our various clients' needs:
· "Customer Staged Solution," under which we supply an inventory of our
Express® Shippers to our customer, in an uncharged state, enabling our
customer (after training/certification) to charge them with liquid nitrogen
and use our Cryoportal™ to enter orders with shipping and delivery service
providers for the transportation of the package. Once the order is released,
our customer services professionals monitor the shipment and the return of the
shipper to us for cleaning, quality assurance testing, and reuse.
· "Customer Managed Solution," a limited customer implemented solution, whereby
we supply our Cryoport Express® Shippers to clients in a fully charged state,
but leaving it to the client to manage the shipping, including the selection
of the shipping and delivery service provider and the return of the shipper to
us. Under this Solution, the customer accepts a significant level of the risk
for a successful shipment. · "Powered by CryoportSM" is made available to providers of shipping and
delivery services who seek to offer a "branded" cryogenic shipping solution as
part of their service offerings. By negotiation, this solution can be private
labeled as long as "powered by CryoportSM" appears prominently on the offering
software interface and prominently on the packaging, which is provided by the
client after minimum volume requirements are met.
· "Integrated Solution" is our most comprehensive and complex outsourcing
solution. It usually involves our management of the entire cryogenic logistics
process for our client, including the location of our employees at the client's site to manage the client's cryogenic logistics, in total. · "
Life Science Point-of-Care Repository Solution" whereby we supply our
Cryoport Express® Shippers to ship and store cryogenically preserved life
science products for up to 6 days (or longer periods with substitute Shippers)
at a point-of-care site, with the Cryoport Express® Shippers serving as a
temporary freezer/repository enabling the efficient distribution of
temperature sensitive allogeneic cell-based therapies without the expense,
inconvenience, and potential costly failure of an on-sight, cryopreservation
apparatus. Our customer services professionals monitor each shipment
throughout the predetermined process including the shipment's return to
assurance and then returned to inventory for reuse.
· "Personalized Medicine and Cell-based Immunotherapy Solution" whereby our
Cryoport Express® Solutions serves as an enabling technology for the safe
manufacture of the rapidly expanding autologous cellular-based immunotherapy
market by providing a comprehensive logistics solution for the verified chain
of custody and condition transport from, (a) the collection of the patient's
cells in a hospital setting, to (b) a central processing facility where they
are manufactured into a personalized medicine, to (c) the safe, cryogenically
preserved return of these irreplaceable cells to a point-of-care treatment
facility. The Cryoport Express® Shippers can then serve as a temporary
freezer/repository to allow the efficient distribution of this personalized
medicine to patients when and where they need it most without the expense,
inconvenience, and potential costly failure of an on-sight, cryopreservation
apparatus. Our customer services professionals monitor each shipment throughout
the predetermined process including the shipment's return to
Cryoport Express® Shipper is cleaned, tested for quality assurance and then
returned to inventory for reuse. 28
One of our distribution partners is
Federal Express Corporation("FedEx"). We have an agreement with FedEx to provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport'sservices for frozen temperature-controlled cold chain transportation as its FedEx® Deep Frozen Shipping Solution, on a non-exclusive basis and at its sole expense. During fiscal year 2013, the Company worked closely with FedEx to further align its sales efforts and accelerate penetration within FedEx's life sciences customer base through improved processes, sales incentives, joint customer calls and more frequent communication at the sales and executive level. In addition, FedEx has developed a FedEx branded version of the CryoportalTM software platform, which is "powered by Cryoport," for use by FedEx and its customers giving them access to the full capabilities of our logistics management platform. In January 2013, we entered into a master agreement ("FedEx Agreement") with FedEx renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our CryoportalTM for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013and, unless sooner terminated as provided in the FedEx Agreement, expires on December 31, 2015. Pursuant to an agreement with DHL Express (USA), Inc.("DHL"), DHLbiotechnology and life science customers have direct access to our cloud-based order entry and tracking portal to order Cryoport Express® Shippers and receive preferred DHLshipping rates. The agreement covers DHLshipping discounts that may be used to support our customers using our Cryoport Express® Solutions. In connection with the agreement, we have integrated our proprietary CryoportalTM to DHL'stracking and billing systems to provide DHLbiotechnology and life science customers with a seamless way ("powered by Cryoport") of shipping their critical biological material worldwide. In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, the Company is providing on-site logistics personnel and its logistics management platform, the CryoportalTM, to manage shipments from the Zoetis manufacturing site in the United Statesto domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoportis constantly analyzing shipping data and processes to further streamline Zoetis' logistics, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum uses of resources. The Company manages Zoetis' total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013, the agreement was amended to expand Cryoport'sscope to manage all logistics of Zoetis' key frozen poultry vaccine to all Zoetis' international distribution centers as well as all domestic shipments of this vaccine. In October 2013, the agreement was further amended to further expand Cryoport'sservices to include the logistics management for a second poultry vaccine. In February 2014, we entered into a services agreement with Liventa Bioscience, Inc.("Liventa"), a commercial stage biotechnology company focused on cell-based, advanced biologics in the orthopedic industry. Under this agreement, Liventa will be using Cryoport Express® Solutions for the logistics of its cell-based therapies requiring cryogenic temperatures and also provide CryoportExpress®Solutions to other biologics suppliers within the orthopedic arena. The agreement combines Cryoport'sproprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa's distribution capability to orthopedic care providers. The implementation of Cryoport'ssolution will eliminate the need for expensive onsite cryogenic freezers for storage of cell-based orthopedic therapies. This will enable Liventa to better serve physicians at the point-of-care, whether at hospitals, clinics, pharmacies, family practices, surgery centers or orthopedic offices. We offer our solutions to companies in the life sciences industry and specific verticals including manufacturers of stem cells and cell lines, diagnostic laboratories, bio-pharmaceuticals, contract research organizations, in-vitro fertilization, cord blood, vaccines, tissue, animal husbandry, and other producers of commodities requiring reliable frozen solutions for logistics. These companies operate within heavily regulated environments and as such, changing vendors and distribution practices typically require a number of steps; which may include the audit of our facilities, review of our procedures, qualifying us as a vendor, and performing test shipments. This process can take up to nine months or longer to complete prior to a potential customer adopting one or more of the Cryoport Express® Solutions. 29 Going Concern
As reported in the Report of Independent Registered Public Accounting Firm to our
March 31, 2014and 2013 consolidated financial statements, we have incurred recurring losses and negative cash flows from operations since inception. These factors, among others, raise substantial doubt about our ability to continue as a going concern.
We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express®Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at
March 31, 2014, and funds currently being raised through a preferred stock offering together with the revenues generated from our services will be sufficient to sustain our planned operations into the second quarter of fiscal year 2015; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern. Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express® Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis on acceptable terms or at all. Management's inability to successfully achieve significant revenue increases or its cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, the Company is seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity. While we increased revenue year-over-year by 142% to $2.7 millionfor the fiscal year ended March 31, 2014, our revenue is still significantly lower than our operating expenses during the year and we have no assurance of the level of future revenues. We incurred a net loss of $19.6 millionand used cash of $4.4 millionin our operating activities during the year ended March 31, 2014. We had negative working capital of $2.9 million, and had cash and cash equivalents
$369,600at March 31, 2014.
We are currently funding our operations through a preferred stock offering (see Note 15 in the accompanying consolidated financial statements) and plan to raise additional funds through additional debt or equity offerings to cover general working capital needs and sales and marketing initiatives to expand our customer base and increase sales. There is no assurance that funds can be secured or if these funds would allow us to continue our operations until more significant revenues can be generated or more funding can be secured. These matters raise substantial doubt about our ability to continue as a going concern.
Liquidity and Capital Resources
March 31, 2014, the Company had cash and cash equivalents of $369,600and negative working capital of $2.9 million. As of March 31, 2013, the Company had cash and cash equivalents of $563,100and negative working capital of $1.5 million. Historically, we have financed our operations primarily through sales of our debt and equity securities. From March 2005through March 2014, we have received net proceeds of approximately $37.6 millionfrom sales of our common stock and the issuance of promissory notes, warrants and debt.
Net Cash Used In Operating Activities
For the year ended
March 31, 2014, we used $4.4 millionof cash for operations primarily as a result of the net loss of $19.6 millionoffset by non-cash expenses of $15.4 millionprimarily comprised of debt conversion expense of $13.7 million, amortization of debt discount and deferred financing costs of $678,900, stock compensation expense of $678,100, depreciation and amortization of $311,600which was partially offset by a change in fair value of derivative instruments of $20,800. Net operating losses decreased primarily as a result of increase in net revenues. Also contributing to the cash impact of our net operating loss (excluding non-cash items) was an increase in accounts receivable of $323,600.
Net Cash Used In Investing Activities
Net cash used in investing activities totaled
$138,900during the year ended March 31, 2014and was attributable to the purchase of property and equipment, primarily the increase in Cryoport Express® High Volume Shipper to meet expected customer demand. 30
Net Cash Provided By Financing Activities
Net cash provided by financing activities totaled
$4.3 millionduring the year ended March 31, 2014, which resulted from proceeds from the issuance of convertible debt of $4.6 millionand proceeds from the exercise of stock options and warrants of $326,900, partially offset by the payment of financing costs of $463,200and the repayment of related party notes payable of $96,000. As discussed in Note 1 of the accompanying consolidated financial statements, there exists substantial doubt regarding the Company's ability to continue as a going concern. The Company issued unsecured convertible promissory notes in principal amount of $1.8 millionin the third and fourth quarters of fiscal 2014. In addition, the Company is currently raising funds through a preferred stock offering as further described in Note 15 in the accompanying consolidated financial statements. The funds raised are being used for working capital purposes and to continue our sales efforts to advance the Company's commercialization of the Cryoport Express® Solutions. However, the Company's management recognizes that the Company will need to obtain additional capital to fund its operations until sustained profitable operations are achieved. Management is currently working on such funding alternatives in order to secure sufficient operating capital through the end of fiscal year 2015. In addition, management will continue to review its operations for further cost reductions to extend the time that the Company can operate with its current cash on hand and additional bridge financing and to utilize third parties for services such as its international recycling and refurbishment centers to provide for greater flexibility in aligning operational expenses with the changes in sales volumes. Results of Operations
Results of Operations for Fiscal 2014 Compared to Fiscal 2013
The following table summarizes certain information derived from our consolidated statements of operations: Year Ended March 31, 2014 2013 $ Change % Change ($ in 000's) Revenues
$ 2,660 $ 1,101 $ 1,559141.7 % Cost of revenues (2,223 ) (1,588 ) (635 ) 40.0 % Gross margin (loss) 437 (487 ) 924 189.7 %
Selling, general and administrative (5,106 ) (5,412 )
306 (5.6 )% Research and development (409 ) (425 ) 16 (3.8 )% Debt conversion expense (13,714 ) - (13,714 ) 100 % Interest expense (784 ) (72 ) (712 ) 976.6 % Change in fair value of derivative liabilities 21 16 5 26.5 % Other expense (8 ) - (8 ) 100 % Provision for income taxes (2 ) (2 ) - - Net loss
$ (19,565 ) $ (6,382 ) $ (13,183 )206.6 % Revenues. We generated revenues from customers in all of our target life sciences markets, such as biotech and diagnostic companies, pharmaceutical companies, central laboratories, contract research organizations, the reproductive medicine market/in vitro fertilization market, and research institutions. Net revenues were $2.7 millionfor the year ended March 31, 2014, as compared to $1.1 millionfor the year ended March 31, 2013. This $1.6 millionor 142% increase is primarily driven by the ramp up and expansion of logistics services provided to Zoetis, an increase in revenues in the reproductive medicine/in vitro fertilization market and an overall increase in both, the number of customers utilizing our services and frequency of shipments compared to the prior year. Our revenues from Zoetis increased to $820,600for the year ended March 31, 2014from $62,300during the prior year. This reflects the successful implementation and expansion of our integrated model with Zoetis, which commenced in February of 2013, whereby we manage the cryogenic shipments of a certain vaccine, both domestically and globally, and in October of 2013 expanded our services to include the logistics management for a second vaccine. The increase in revenues in the reproductive medicine/in vitro fertilization market was particularly strong, with revenues increasing from $238,000to $614,000, an increase of $376,000or 158%. This is partially the result of targeted telemarketing activities and email marketing campaigns to broaden the awareness of our solution in this space. Gross margin and cost of revenues. Gross margins for the year ended March 31, 2014was 16.4% of revenues, as compared to a gross loss of 44.3% of revenues for the prior year. The increase in gross margin is primarily due to the increase in net revenue combined with a reduction in freight as a percentage of revenues and a decrease of fixed manufacturing costs. Cost of revenues for the year ended March 31, 2014was 83.6% of revenues, as compared to 144.3% of revenues for the prior year. Our cost of revenues are primarily comprised of freight charges, payroll and related expenses related to our operations center in California, third-party charges for our European and Asian operations centers in Hollandand Singapore, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions. The increase in cost of revenues is primarily due to freight charges from the growth in shipments. 31 Selling, general and administrative expenses. Selling, general and administrative expenses decreased $306,000, or 5.6% for the year ended March 31, 2014as compared to the prior year. This decrease is primarily related to a severance payment of approximately $180,000paid to the former Chief Executive Officer in April 2012and a decrease in board of director stock-based compensation. Partially offsetting these decreases is an increase in compensation related to replacement of the Chief Executive Officer and an increase in expenses related to sales and marketing activities compared to previous year. Research and development expenses. Research and development expenses decreased $16,000or 3.8% for the year ended March 31, 2014, as compared to the prior year. Our research and development efforts are focused on continually improving the features of the Cryoport Express® Solutions including the Company's cloud-based logistics management platform, the CryoportalTM, the CryoportExpress® Shippers and development of additional accessories to facilitate the efficient shipment of life science commodities using our solution. We use an outside software development company and other third parties to provide some of these services. Research and development expenses to date have consisted primarily of costs associated with the continually improving the features of the Cryoport Express® Solution including the web based customer service portal and the Cryoport Express® Shippers. Further, these efforts are expected to lead to the introduction of shippers of varying sizes based on market requirements, constructed of lower cost materials and utilizing high volume manufacturing methods that will make it practical to provide the cryogenic packages offered by the Cryoport Express®Solution. Other research and development effort has been directed toward improvements to the liquid nitrogen retention system to render it more reliable in the general shipping environment and to the design of the outer packaging. Alternative phase change materials in place of liquid nitrogen may be used to increase the potential markets these shippers can serve such as ambient and 2°-8°C markets. Debt conversion expense. Debt conversion expense for the year ended March 31, 2014of $13.7 millionwas related to the induced conversion of $4,127,200of aggregate principal and accrued interest from the convertible bridge notes into shares of common stock and warrants. Debt conversion expense represents the fair value of the securities transferred in excess of the fair value of the securities issuable upon the original conversion terms of the bridge notes.
Company calculated the fair value of the common stock issued by using the closing price of the stock on the date of issuance. The fair value of the warrants was calculated using the Black-Scholes option pricing model.
Interest expense. Interest expense increased
$712,000for the year ended March 31, 2014, as compared to the prior year. Interest expense for the year ended March 31, 2014included amortization of the debt discount and deferred financing fees of approximately $678,900, interest expense on our bridge notes of approximately $71,600and accrued interest on our related party notes payable of approximately $36,500. Interest expense for the year ended March 31, 2013included amortization of the debt discount of approximately $17,500, interest expense on our convertible debentures of approximately $9,900and accrued interest on our related party notes payable of approximately $42,200.
Change in fair value of derivative liabilities. The gain for the year ended
Other expense, net. The other expense, net for the year ended
March 31, 2014is primarily due to administrative charges and foreign exchange losses on accounts receivable and payable invoices.
Off-Balance Sheet Arrangements
We do not have any off balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.
The following table summarizes our contractual obligations as of
March 31, 2014, and the effects such obligations are expected to have on liquidity and cash flow in future periods ($ in '000's): Less than After Total 1 Year 1-3 Years 4-5 Years 5 Years
Contractual obligations Operating lease obligations(1)
$ 220 $ 193$ 27 $ - $ - Bridge notes(2) 1,807 1,807 - - - Other long-term obligations (3) 1,358 1,358 - - - Total $ 3,385 $ 3,358$ 27 $ - $ - 32
(1) The operating lease obligations are primarily related to the facility lease
for our principal executive office in
(2) Bridge notes represent unsecured convertible promissory notes and accrued
interest at 5% per annum which were issued in the third and fourth quarter
of 2014 to certain accredited investors pursuant to the terms of
subscription agreements and letters of investment intent. All principal and
accrued interest is due
(3) Other long-term obligations represent outstanding unsecured indebtedness and
accrued interest owed to four related parties which bear interest at the rate
of 6% per annum. Any unpaid principal and accrued interest is due at maturity
on various dates through
March 1, 2015. Impact of Inflation
From time to time,
Critical Accounting Policies and Estimates
Our discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities reported in our consolidated financial statements. The estimation process requires assumptions to be made about future events and conditions, and is consequently inherently subjective and uncertain. Actual results could differ materially from our estimates. The
SECdefines critical accounting policies as those that are, in management's view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies to be critical to an understanding of our consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows. See Note 2: "Summary of Significant Accounting Policies" of our accompanying consolidated financial statements for a description of our critical accounting policies and estimates.
New Accounting Pronouncements
See Note 2: "Recent Accounting Pronouncements" of our accompanying consolidated financial statements for a description of recent accounting pronouncements that may have a significant impact on our financial reporting and our expectations of their impact on our results of operations and financial condition.